Status:
COMPLETED
NK Cells Treatment for COVID-19
Lead Sponsor:
Xinxiang medical university
Collaborating Sponsors:
First Affiliated Hospital of Xinjiang Medical University
Conditions:
Novel Coronavirus Pneumonia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCo...
Eligibility Criteria
Inclusion
- 1\. Male or female, aged at 18 years-65 years old
- 2\. Pneumonia that is judged by chest radiograph or computed tomography
- 3\. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain reaction(RT-PCR) from any diagnostic sampling source
Exclusion
- 1\. Pregnancy or breastfeeding
- 2\. Known HIV, HBV or HCV infection
- 3\. Patients with malignant tumor, other serious systemic diseases and psychosis
- 4\. Patients who are participating in other clinical trials
- 5\. Inability to provide informed consent or to comply with test requirements
Key Trial Info
Start Date :
February 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04280224
Start Date
February 15 2020
End Date
December 31 2022
Last Update
February 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453000